

Denis Malvy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8114097/publications.pdf>

Version: 2024-02-01

43
papers

3,363
citations

394286

19
h-index

243529

44
g-index

46
all docs

46
docs citations

46
times ranked

6952
citing authors

#	ARTICLE	IF	CITATIONS
1	High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea. <i>IDCases</i> , 2022, 27, e01412.	0.4	2
2	Plasma Markers of Neutrophil Extracellular Trap Are Linked to Survival but Not to Pulmonary Embolism in COVID-19-Related ARDS Patients. <i>Frontiers in Immunology</i> , 2022, 13, 851497.	2.2	13
3	Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE). <i>Clinical Microbiology and Infection</i> , 2022, 28, 1010-1016.	2.8	21
4	Post-vaccination SARS-cov-2 infection in nursing home residents, Bordeaux, France. <i>Journal of Clinical Virology</i> , 2022, 149, 105134.	1.6	1
5	Travel-related infections presenting in Europe: A 20-year analysis of EuroTravNet surveillance data. <i>Lancet Regional Health - Europe</i> , The, 2021, 1, 100001.	3.0	27
6	Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study. <i>The Lancet Global Health</i> , 2021, 9, e469-e478.	2.9	30
7	Incidental infiltrated gallbladder in a migrant from Ivory Coast: A diagnostic challenge. <i>Travel Medicine and Infectious Disease</i> , 2021, 41, 102061.	1.5	0
8	Clinical presentation, outcomes and factors associated with mortality: A prospective study from three COVID-19 referral care centres in West Africa. <i>International Journal of Infectious Diseases</i> , 2021, 108, 45-52.	1.5	14
9	Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2. <i>Antiviral Research</i> , 2021, 193, 105137.	1.9	32
10	Post-exposure prophylaxis following high-risk contact with Ebola virus, using immunotherapies with monoclonal antibodies, in the eastern Democratic Republic of the Congo: an emergency use program. <i>International Journal of Infectious Diseases</i> , 2021, 113, 166-167.	1.5	9
11	Severe toxoplasmosis imported from tropical Africa in immunocompetent patients: A case series. <i>Travel Medicine and Infectious Disease</i> , 2020, 35, 101509.	1.5	14
12	COVID-19: France grapples with the pragmatics of isolation. <i>Lancet Public Health</i> , The, 2020, 5, e573-e574.	4.7	13
13	France's COVID-19 response: balancing conflicting public health traditions. <i>Lancet</i> , The, 2020, 396, 219-221.	6.3	20
14	Clinical and virological data of the first cases of COVID-19 in Europe: a case series. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 697-706.	4.6	953
15	The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008259.	1.3	13
16	Detection of Zika Virus Replication in Human Semen by Reverse-Transcription Polymerase Chain Reaction Targeting of Antisense Ribonucleic Acid. <i>Journal of Infectious Diseases</i> , 2020, 222, 319-323.	1.9	5
17	Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE). <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101557.	1.5	5
18	Zika among international travellers presenting to GeoSentinel sites, 2012-2019: implications for clinical practice. <i>Journal of Travel Medicine</i> , 2020, 27, .	1.4	18

#	ARTICLE	IF	CITATIONS
19	Travel-associated chikungunya acquired in Myanmar in 2019. <i>Eurosurveillance</i> , 2020, 25, .	3.9	16
20	Early complicated schistosomiasis in a returning traveller: Key contribution of new molecular diagnostic methods. <i>International Journal of Infectious Diseases</i> , 2019, 79, 72-74.	1.5	10
21	Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: The ANRS VIHVO cohort study. <i>Travel Medicine and Infectious Disease</i> , 2019, 29, 40-47.	1.5	5
22	Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015â€”A Retrospective Observational Study. <i>Journal of Infectious Diseases</i> , 2019, 220, 195-202.	1.9	38
23	Ebola virus disease. <i>Lancet, The</i> , 2019, 393, 936-948.	6.3	305
24	The exacerbation of Ebola outbreaks by conflict in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24366-24372.	3.3	72
25	Probable Sexually Transmitted Zika Virus Infection in a Pregnant Woman. <i>New England Journal of Medicine</i> , 2018, 378, 1458-1460.	13.9	19
26	Review: Chikungunya Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. <i>Arthritis and Rheumatology</i> , 2018, 70, 484-495.	2.9	75
27	Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. <i>The Lancet Global Health</i> , 2017, 5, e80-e88.	2.9	100
28	How to treat Ebola virus infections? A lesson from the field. <i>Current Opinion in Virology</i> , 2017, 24, 9-15.	2.6	15
29	Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005389.	1.3	153
30	Zika beyond the Americas: Travelers as sentinels of Zika virus transmission. A GeoSentinel analysis, 2012 to 2016.. <i>PLoS ONE</i> , 2017, 12, e0185689.	1.1	36
31	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	3.9	382
32	What Do People Know and Believe about Vitamin D?. <i>Nutrients</i> , 2016, 8, 718.	1.7	30
33	Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days. <i>Clinical Infectious Diseases</i> , 2016, 63, 1353-1356.	2.9	201
34	A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. <i>New England Journal of Medicine</i> , 2016, 375, 1448-1456.	13.9	429
35	Strongyloidiasis in a young French woman raises concern about possible ongoing autochthonous transmission in Spain. <i>International Journal of Infectious Diseases</i> , 2016, 42, 43-44.	1.5	10
36	Concurrent malaria and arbovirus infections in Kedougou, southeastern Senegal. <i>Malaria Journal</i> , 2016, 15, 47.	0.8	84

#	ARTICLE	IF	CITATIONS
37	Strategies evaluation in environmental conditions by symbolic data analysis: application in medicine and epidemiology to trachoma. <i>Advances in Data Analysis and Classification</i> , 2015, 9, 107-119.	0.9	2
38	Visceral leishmaniasis due to <i>Leishmania infantum</i> in a kidney transplant recipient living in France. <i>Travel Medicine and Infectious Disease</i> , 2015, 13, 115-116.	1.5	10
39	Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report. <i>Malaria Journal</i> , 2014, 13, 398.	0.8	36
40	Disseminated cysticercosis revealed by subcutaneous nodules in a migrant from Cameroon. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 551-552.	1.5	2
41	Accidental intestinal myiasis caused by <i>Eristalis tenax</i> in France. <i>Travel Medicine and Infectious Disease</i> , 2014, 12, 109-110.	1.5	12
42	Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. <i>BMC Infectious Diseases</i> , 2009, 9, 200.	1.3	100
43	Risk of malaria among French adult travellers. <i>Travel Medicine and Infectious Disease</i> , 2006, 4, 259-269.	1.5	19